Facebook Youtube Instagram Linkedin-in

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Zug, Switzerland:   Ad hoc announcement pursuant to Art. 53 LR   Approximately 7% of people in the United States

READ MORE

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

Zug, Switzerland:   Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent

READ MORE

UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment

Orismilast Phase 2b results in atopic dermatitis (AD) presented today as a late-breaking oral presentation at the European Academy of

READ MORE

New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations

Zug, Switzerland:    New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be

READ MORE

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation Additionally, two posters on data

READ MORE

Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.

Quick Links

Contact Us

Stay Updated

Facebook Youtube Instagram Linkedin-in

Share Your Message!

Copyright© 2025 Creative Bharat Powered By A Buzz Company